RT Journal Article
SR Electronic
T1 <em>CTLA4</em> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e002949
DO 10.1136/jitc-2021-002949
VO 9
IS 8
A1 Klümper, Niklas
A1 Ralser, Damian J
A1 Zarbl, Romina
A1 Schlack, Katrin
A1 Schrader, Andres Jan
A1 Rehlinghaus, Marc
A1 Hoffmann, Michèle J
A1 Niegisch, Günter
A1 Uhlig, Annemarie
A1 Trojan, Lutz
A1 Steinestel, Julie
A1 Steinestel, Konrad
A1 Wirtz, Ralph M
A1 Sikic, Danijel
A1 Eckstein, Markus
A1 Kristiansen, Glen
A1 Toma, Marieta
A1 Hölzel, Michael
A1 Ritter, Manuel
A1 Strieth, Sebastian
A1 Ellinger, Jörg
A1 Dietrich, Dimo
YR 2021
UL http://jitc.bmj.com/content/9/8/e002949.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.